Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2/3 1

Status

Completed 4

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 11Lymphoid 10Genitourinary 6Other solid neoplasm 5Thoracic 4Plasma cell 4Dermatologic 4Sarcoma 3Myeloid 3Gastrointestinal 3Head & Neck 2Gynecologic 2CNS 2Breast 2Tumor-Agnostic 1Other neoplasm 1Endocrine 1

Conditions

Multiple Myeloma 4Recurrence 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Dexamethasone 393Bortezomib 246Lenalidomide 222Cyclophosphamide 184Melphalan 168Calcium Dobesilate 119Peripheral Blood Stem Cell Transplantation 94fludarabine phosphate 89Thalidomide 82Filgrastim 74carfilzomib 70pomalidomide 68Granulocyte Colony-Stimulating Factor 63Busulfan 63Mycophenolic Acid 61daratumumab 58Whole-Body Irradiation 57ixazomib 54fludarabine 52Tacrolimus 52Prednisone 51Cyclosporine 50Antilymphocyte Serum 35dexamethasone acetate 32plerixafor 30Etoposide 30Methotrexate 29Radiotherapy 28dexamethasone 21-phosphate 27Doxorubicin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × tanespimycin × Plasma cell × Clear all
NCT00514371 2015-12-07

TIME-2

Bristol-Myers Squibb

Phase 2/3 Completed
22 enrolled
Plasma cell

Multiple Myeloma

NCT00303797 2013-03-19

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
50 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00546780 2011-06-28

BMS TIME-1

Bristol-Myers Squibb

Phase 3 Completed
31 enrolled
Plasma cell

Multiple Myeloma

NCT00113204 2008-05-20

IPi-504-01

Infinity Pharmaceuticals, Inc.

Phase 1 Completed
18 enrolled
Other hematologic neoplasmPlasma cell

Hematologic Diseases, Multiple Myeloma, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡